Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
-
Clinical Benefit
Substantial
The Actual Benefit of ZYPREXA and ZYPREXA VELOTAB in the treatment of schizophrenia remains substantial.
Clinical Added Value
moderate
ZYPREXA and ZYPREXA VELOTAB, as with all other anti-psychotics (including first generation anti-psychotics), provide a moderate Improvement in Actual Benefit (IAB III) in the treatment of schizophrenia.
Listen
